- Community-Beiträge
- Aktuellste Threads
Werden Sie mit Ihrer Handelsstrategie der Trader 2026 und gewinnen Sie einen Range Rover Evoque. Hier anmelden!
| Geld/Brief | 14,84 $ / 36,04 $ |
| Spread | +142,86% |
| Schluss Vortag | 22,20 $ |
| Gehandelte Stücke | 17.861 |
| Tagesvolumen Vortag | 483.578,6 $ |
| Tagestief 21,94 $ Tageshoch 22,78 $ | |
| 52W-Tief 11,23 $ 52W-Hoch 35,00 $ | |
| Jahrestief 16,92 $ Jahreshoch 35,00 $ | |
| Umsatz in Mio. | 3,48 $ |
| Operatives Ergebnis (EBIT) in Mio. | -42,09 $ |
| Jahresüberschuss in Mio. | -242,03 $ |
| Umsatz je Aktie | 0,46 $ |
| Gewinn je Aktie | -26,60 $ |
| Gewinnrendite | -6.960,77% |
| Umsatzrendite | -6.960,77% |
| Return on Investment | -245,15% |
| Marktkapitalisierung in Mio. | 282,20 $ |
| KGV (Kurs/Gewinn) | -0,85 |
| KBV (Kurs/Buchwert) | - |
| KUV (Kurs/Umsatz) | 59,47 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | -190,18% |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| AMEX | 23,60 $ | 0 % | 23,60 $ | 25.08.26 | |
| Nasdaq | 22,63 $ | +1,94% | 22,20 $ | 02.09.26 | |
| NYSE | 22,61 $ | +2,12% | 22,14 $ | 02.09.26 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 02.09.26 | 22,63 | 400 T |
| 01.09.26 | 22,20 | 484 T |
| 31.08.26 | 22,02 | 0,71 M |
| 28.08.26 | 22,42 | 0,51 M |
| 27.08.26 | 24,01 | 0,52 M |
| 26.08.26 | 23,71 | 303 T |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 23,71 $ | -4,56% |
| 1 Monat | 22,21 $ | +1,89% |
| 6 Monate | 28,60 $ | -20,87% |
| 1 Jahr | 12,02 $ | +88,27% |
| 5 Jahre | 104,70 $ | -78,39% |
| Marktkapitalisierung | 282,20 Mio. $ |
| Streubesitz | -3,29% |
| Währung | USD |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +12,69% | TCG Crossover Management, LLC |
| +6,64% | Kalehua Capital Management LLC |
| +6,60% | Boxer Capital Management, LLC |
| +6,30% | Millennium Management LLC |
| +6,22% | StemPoint Capital LP |
| +5,45% | VR Adviser, LLC |
| +3,72% | Spruce Street Capital LP |
| +3,41% | BRAIDWELL LP |
| +3,34% | 5AM Venture Management, LLC |
| +2,92% | Vestal Point Capital LP |
| +2,43% | Vanguard Morn Total Stk Mkt Idx Investor |
| +2,40% | Vanguard MStar Total Stk Mkt Idx Invest |
| +2,24% | Vivo Capital, LLC |
| +1,98% | Perceptive Advisors LLC |
| +1,96% | Woodline Partners LP |
| +1,76% | Balyasny Asset Management LLC |
| +1,54% | iShares Russell 2000 ETF |
| +1,49% | Longwood Capital Partners LLC |
| +1,49% | Ikarian Capital, LLC |
| +1,46% | Vanguard Capital Management, LLC |
| +1,38% | Ameriprise Financial Inc |
| +1,24% | SILVERARC CAPITAL MANAGEMENT, LLC |
| +1,15% | Regents Of The University Of California |
| +0,89% | Vanguard Institutional Extnd Mkt Idx Tr |
| +0,59% | iShares Russell 2000 Growth ETF |
| +0,43% | Alger Life Sciences Innovation Composite |
| +0,38% | Russell 2000 Index Non-Lendable Fund |
| +0,38% | Russell 2000 Equity Index Fund B |
| +0,37% | Vanguard Russell 2000 ETF |
| +0,35% | State St Russell Sm/Mid Cp® Indx SL Cl I |
| +0,24% | State St Russell Sm Cap® Idx SL Cl I |
| +0,23% | Fidelity Extended Market Index |
| +0,21% | iShares Micro-Cap ETF |
| +0,18% | BlackRock Extended Equity Market Fund K |
| +0,15% | Fidelity Series Total Market Index |
| +0,14% | Schwab Small Cap Index |
| +0,14% | NT R2000 Index Fund - NL |
| +0,13% | Spartan Extended Market Index Pool F |
| +0,13% | Blackrock Extended Mkt Fund CF |
| +0,13% | Extended Equity Market Fund B |
| +0,13% | Extended Equity Market Fund E |
| +0,12% | NT R2000 Index Fund - DC - NL - 3 |
| +0,1% | Goldman Sachs ActiveBeta® US SmCp Eq ETF |
| +100,114% | Institutionelle Aktionäre |
| +3,176% | Insider Aktionäre |
| -3,29% | Streubesitz |
Zahlen für Q2/23
-SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023
-SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data expected by the end of 2023
-Corporate prioritization efforts expected to provide cash runway extension into 2025
https://investors.surrozen.com/news-releases/news-release-details/surrozen-provides-second-quarter-2023-financial-results
Zahlen für Q1/23
- cash runway into the second half of 2024
- SZN-043 Phase 1a with safety data expected by the end of 2023
- SZN-1326 Phase 1a with safety data expected by the end of 2023
https://investors.surrozen.com/news-releases/news-release-details/surrozen-provides-first-quarter-2023-financial-results-and
Mit Cash für ca. 4 Quartalen könnten sich die beiden Katalysatoren in Q4 noch gut mitnehmen lassen.